Entering text into the input field will update the search result below

Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Sep. 27, 2022 11:40 AM ETBellerophon Therapeutics, Inc. (BLPH) StockBy: Anuron Mitra, SA News Editor

Human lungs healthcare and medical abstract background

Silver Place/iStock via Getty Images

  • Bellerophon Therapeutics (NASDAQ:BLPH) on Tuesday said the U.S. FDA had accepted the company's proposal to reduce the study size of its ongoing phase 3 trial of its nitric oxide treatment for fibrotic interstitial lung

Recommended For You

More Trending News

About BLPH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BLPH--
Bellerophon Therapeutics, Inc.